Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

STAT3 inhibitor DSP-0337

An orally administered prodrug of napabucasin, a small molecule cancer stemness inhibitor with potential antineoplastic activity. Upon administration, DSP-0337 is converted to its active form, napabucasin. Napabucasin targets and inhibits signal transducer and activator of transcription 3 (STAT3), thereby preventing STAT-3-mediated signaling. The STAT3 pathway is overly active in many cancer types and is implicated in cancer stem cell-mediated growth, recurrence and resistance to conventional chemotherapies.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	cancer stemness inhibitor DSP-0337 napabucasin prodrug DSP-0337
Code name:	DSP 0337 DSP-0337

STAT3 inhibitor DSP-0337

Search NCI's Drug Dictionary